stockportfolio.pro
Stocks / RPRX vs ZTS
RPRX vs ZTS
Royalty Pharma plc and Zoetis Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Royalty Pharma plc (RPRX) | Zoetis Inc. (ZTS) | |
|---|---|---|
| Market cap | $31.6B | $33.5B |
| Revenue (latest FY) | $2.38B | $9.47B |
| Net income (latest FY) | $770.95M | $2.67B |
| Revenue growth (5y CAGR) | 2.3% | 7.2% |
| Net margin | 32.4% | 28.2% |
| Return on equity | 11.9% | 78.3% |
| P/E ratio | 28.9 | 13.1 |
| Dividend yield | 1.7% | 2.7% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | — | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RPRX — free Open ZTS — freeFrequently asked questions
Which is bigger, RPRX or ZTS?
Zoetis Inc. is larger by market capitalization — $33.5B versus $31.6B.
Which grows faster, RPRX or ZTS?
Over the last five fiscal years, Zoetis Inc. grew revenue faster — 7.2%/yr versus 2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.